PAUL J. EDELSON, M.D.; CRAIG E. METROKA, M.D., Ph.D.; ALVIN FRIEDMAN-KIEN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Pneumocystis pneumonia occurs in about 60% of patients with the acquired immunodeficiency syndrome (AIDS) (1), and in many may recur. However, therapy with either trimethoprim-sulfamethoxazole or pentamidine carries substantial risks of severe side effects (2). Because dapsone (4,4′-diaminodiphenylsulfone) has been effective in a rat model of pneumocystis infection (3), we studied its safety in patients with AIDS who have previously had severe reactions to trimethoprim-sulfamethoxazole.
Four patients were closely monitored while they received 25 to 200 mg of drug daily for up to 1 year. All were initially screened for glucose-6-phosphate dehydrogenase deficiency. Patients were begun on
EDELSON PJ, METROKA CE, FRIEDMAN-KIEN A. Dapsone, Trimethoprim-Sulfamethoxazole, and the Acquired Immunodeficiency Syndrome. Ann Intern Med. ;103:963. doi: 10.7326/0003-4819-103-6-963
Download citation file:
Published: Ann Intern Med. 1985;103(6_Part_1):963.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use